RIGL Rigel Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RIGL

Price (delayed)

$10.75

Market cap

$188.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.1

Enterprise value

$223.49M

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare ...

Highlights
Rigel Pharmaceuticals's EPS has surged by 58% YoY and by 21% QoQ
The net income has surged by 56% year-on-year and by 21% since the previous quarter
The company's gross profit fell by 12% YoY but it rose by 2.2% QoQ
Rigel Pharmaceuticals's revenue has decreased by 7% YoY but it has increased by 3% QoQ
The quick ratio has contracted by 46% YoY and by 36% from the previous quarter
RIGL's equity is down by 31% YoY and by 11% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rigel.com
Peers: AZN SGMO XOMA AMGN

Key stats

What are the main financial stats of RIGL
Market
Shares outstanding
17.54M
Market cap
$188.56M
Enterprise value
$223.49M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.86
Earnings
Revenue
$120.35M
EBIT
-$12.26M
EBITDA
-$10.98M
Free cash flow
-$6.69M
Per share
EPS
-$1.1
Free cash flow per share
-$0.38
Book value per share
-$1.81
Revenue per share
$6.87
TBVPS
$5.57
Balance sheet
Total assets
$126.52M
Total liabilities
$158.19M
Debt
$60.5M
Equity
-$31.67M
Working capital
$19.29M
Liquidity
Debt to equity
-1.91
Current ratio
1.26
Quick ratio
1.05
Net debt/EBITDA
-3.18
Margins
EBITDA margin
-9.1%
Gross margin
93.2%
Net margin
-16.5%
Operating margin
-12.2%
Efficiency
Return on assets
-16.6%
Return on equity
N/A
Return on invested capital
-17.8%
Return on capital employed
-23%
Return on sales
-10.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RIGL stock price

How has the Rigel Pharmaceuticals stock price performed over time
Intraday
-1.38%
1 week
11.28%
1 month
36.08%
1 year
-15.35%
YTD
-25.86%
QTD
30.78%

Financial performance

How have Rigel Pharmaceuticals's revenue and profit performed over time
Revenue
$120.35M
Gross profit
$112.19M
Operating income
-$14.73M
Net income
-$19.8M
Gross margin
93.2%
Net margin
-16.5%
RIGL's operating income has surged by 65% year-on-year and by 28% since the previous quarter
The operating margin has soared by 62% YoY and by 30% from the previous quarter
The net income has surged by 56% year-on-year and by 21% since the previous quarter
RIGL's net margin has soared by 52% YoY and by 23% QoQ

Growth

What is Rigel Pharmaceuticals's growth rate over time

Valuation

What is Rigel Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
1.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.86
Rigel Pharmaceuticals's EPS has surged by 58% YoY and by 21% QoQ
RIGL's equity is down by 31% YoY and by 11% from the previous quarter
The stock's price to sales (P/S) is 52% less than its 5-year quarterly average of 3.3 and 17% less than its last 4 quarters average of 1.9
Rigel Pharmaceuticals's revenue has decreased by 7% YoY but it has increased by 3% QoQ

Efficiency

How efficient is Rigel Pharmaceuticals business performance
Rigel Pharmaceuticals's return on sales has surged by 68% YoY and by 35% QoQ
RIGL's return on invested capital has surged by 65% year-on-year and by 26% since the previous quarter
The return on assets has surged by 53% year-on-year and by 22% since the previous quarter

Dividends

What is RIGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RIGL.

Financial health

How did Rigel Pharmaceuticals financials performed over time
Rigel Pharmaceuticals's total assets is 20% less than its total liabilities
RIGL's current ratio is down by 46% year-on-year and by 32% since the previous quarter
The quick ratio has contracted by 46% YoY and by 36% from the previous quarter
RIGL's equity is down by 31% YoY and by 11% from the previous quarter
RIGL's debt to equity is up by 24% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.